Forte Biosciences Inc Stock

$12.25

7.36% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US34962G1094

Symbol

FBRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Forte Biosciences Inc Stock price

$12.25

-342.75 96.55% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.84 7.36%

ISIN

US34962G1094

Symbol

FBRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$149.6m

Enterprise Value

$103.8m

Net debt

$-45.9m

Cash

$45.9m

Shares outstanding

6.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

2.10

Financial Health

Equity Ratio

85.25%

Return on Equity

-66.69%

ROCE

-117.37%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-45.1m | -

EBIT

$-45.1m

Net Income

$-44.2m | $-24.6m

Free Cash Flow

$-34.5m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-34.87% | -

EBIT

-34.92%

Net Income

-37.48% | 29.74%

Free Cash Flow

-14.04%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-3.87

FCF per Share

$-5.25

Short interest

3.58%

Employees

14.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Forte Biosciences Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Forte Biosciences Inc forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Forte Biosciences Inc forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Forte Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	15 15	28% 28% -
- Research and Development Expense	30 30	38% 38% -
EBITDA	-45 -45	35% 35% -
- Depreciation and Amortization	0.04 0.04	100% 100% -
EBIT (Operating Income) EBIT	-45 -45	35% 35% -
Net Profit	-44 -44	37% 37% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Forte Biosciences Inc Stock News

Neutral

Business Wire

●

3 days ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up t...

Neutral

Business Wire

●

4 days ago

Forte Biosciences Announces Proposed Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects ...

Neutral

Business Wire

●

5 days ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Rese...

More Forte Biosciences Inc News

Company Profile

Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.

Head office	United States
CEO	Paul Wagner
Employees	14
Founded	2017
Website	www.fortebiorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now